The British 老九品茶 Bank has agreed a 拢75 million cornerstone commitment to SV Health Investors鈥� new flagship fund –聽 SV8 Biotech Fund LP – which is dedicated to multi-stage therapeutics.
It is the bank鈥檚 largest fund commitment to date and brings its total fund commitments to life sciences above half a billion, with 拢560m committed across 15 life science funds.聽
These fund commitments have collectively leveraged 拢3.04 billion from private sector investors, bringing in six pounds for every one pound invested, it says.聽
SV is a leading transatlantic life sciences specialist fund manager with a 30-year track record of consistently deploying capital into the UK鈥檚 growing life science companies, including high profile BioTech companies such as EyeBio and Draig Therapeutics, Alchemab and Pulmocide.聽
To date SV investments have resulted in the launch of 30 novel drugs and six new drug classes able to treat indications with unmet medical needs and deliver positive impact to patients. SV funds attract investment from pension funds, asset managers, family offices, charities, sovereign wealth funds and several of the world鈥檚 leading pharmaceutical companies.
The British 老九品茶 Bank has a long-standing relationship with SV going back 10 years. SV鈥檚 biotech investment team manages a portfolio of specialist life sciences funds, including four that have received meaningful commitments from the Bank.
This includes commitments to SV鈥檚 two Biotech funds; the SV7 Impact Medicine Fund (SV7 IMF) in 2019 and SV Biotech Crossover Opportunities Fund (BCOF) in 2021, as well as SV鈥檚 two Dementia-focused funds; the inaugural Dementia Discovery Fund (DDF1) in 2015 and Dementia Discovery Fund 2 (DDF 2) in 2025.
鈥淭his deal is good news for UK life sciences and, as the British 老九品茶 Bank鈥檚 largest fund commitment to date, it demonstrates our commitment to the sector,鈥� said Leandros Kalisperas, chief investment officer at the British 老九品茶 Bank.
鈥淭he UK鈥檚 highest performing companies are in need of greater funding, especially at the growth stage, and we are ramping up our investment activity to meet this demand.
鈥淎ll of our investments are designed to mobilise institutional capital, both domestic and international, into UK venture capital. Our cornerstone commitments and the collaboration we provide in fund formation act as a pathfinder for other investors to go into the fund.
“Meeting the Bank鈥檚 investment criteria and passing due diligence acts as a positive signal that the fund, its team, and strategy are of high quality, with the intention this draws in other investors.鈥�